type here...

CATEGORIES

Medication

LATEST

1234Page 3 of 4

TRENDING

EDITORS CHOICE

SUICIDE: IS AI RESPONSIBLE?

Christi Taylor-Jones -
The Raines discovered their son Adam in the closet where he hung himself with the support of a character on ChatGPT with whom he’d...

Is the New York Times a Shill for Promoters of Psychedelics?

James Coyne -
Evidence that the newspaper is not sufficiently detached from promoters to provide an open-minded but skeptical perspective that readers should be able to expect.

FDA Approval of New Drug for Alzheimer’s Offers Hope

Dr Jeff Livingston -
The FDA approves Aduhelm for the treatment of early Alzheimer's disease. Aduhelm targets brain plaque formation to slow the rate of cognitive decline.

Psilocybin as an Antidepressant for Cancer Patients Who Are Not Depressed

James Coyne -
Research concerning the role of psychedelics in mental health treatment and its superb publicity campaign depends on millions of dollars raised by venture capitalists.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories